Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1992-11-13
1995-04-04
Henley, III, Raymond J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514654, A61K 31445, A61K 31135
Patent
active
054038472
ABSTRACT:
A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor, and, binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such .alpha..sub.1C adrenergic receptor. Compounds meeting these criteria are provided.
REFERENCES:
patent: 4975440 (1990-12-01), Flockerzi et al.
patent: 4994461 (1991-02-01), Ulrich
Archibald, J. L., et al., "Antihypertensive Ureidopiperidines," Journal of Medical Chemistry, 23, 857-861 (1980), U.S.A.
Boer, R., et al., "(+)-Niguldipine Binds With Very High Affinity to Ca.sup.2+ Channels and to a Subtype of .alpha..sub.1 -Adrenoreceptors," European Journal of Pharmacology--Molecular Pharmacology Section, 172, 131-145 (1989), The Netherlands.
Lomasney, J. W., et al., "Molecular Cloning and Expression of the cDNA for the .alpha..sub.1A -Adrenergic Receptor," Journal of Biological Chemistry, 266, 6365-69 (1991), U.S.A.
Yamada, S., et al., ".alpha..sub.1A -Adrenergic Receptors in Human Prostate: Characterizatic and Alteration in Benign Prostatic Hypertrophy," Journal of Pharmacology and Experimental Therapeutics, 242, 326-330 (1987), U.S.A.
Lepor & Knapp-Maloney et al., Journal of Urology, vol. 144, Dec. 1990, pp. 1393-1398.
Gup et al., Journal of Urology, vol. 143, Jan. 1990, pp. 179-185.
Lepor & Baumann et al., Medline Abstracts, No. 88317114, 1988.
Lepor & Shapiro et al., Medline Abstracts, No. 88317113, 1988.
Ramarao, C. S., J. Biol. Chem. (1992), "Genomic Organization and Expression of the Human .alpha..sub.1B -Adrenergic Receptor," vol. 267, pp. 21936-21944.
I. Marshall, et al., "Human Alpha.sub.1C -Adrenoceptor: Functional Characterization In Prostate" Abstract No. C97 of an oral presentation given during a Sep. 9-11, 1992 meeting of the British Pharmacological Society (1992).
Branchek Theresa A.
Chiu George
Forray Carlos C.
Gluchowski Charles
Hartig Paul R.
Henley III Raymond J.
Jarvis William R. A.
Synaptic Pharmaceutical Corporation
White John P.
LandOfFree
Use of .alpha..sub.1C specific compounds to treat benign prostat does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of .alpha..sub.1C specific compounds to treat benign prostat, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of .alpha..sub.1C specific compounds to treat benign prostat will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2380891